Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HBM Holdings's EBITDA for the
six
months ended in Dec. 2025 was HK$177 Mil. HBM Holdings's Revenue for the
six
months ended in Dec. 2025 was HK$441 Mil. Therefore, HBM Holdings's EBITDA margin for the quarter that ended in Dec. 2025 was 40.04%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HBM Holdings EBITDA Margin % Related Terms
HBM Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HBM Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02142 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, HBM Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HKSE:02142) has a EBITDA Margin % of 40.04% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HBM Holdings and its competitors. According to the industry distribution chart, HBM Holdings ranks #36 out of 941 companies in the Biotechnology industry, placing it in the top 3.8%.
Is HBM Holdings' EBITDA Margin % too high?
HBM Holdings' current EBITDA Margin % is 40.04%. Based on the distribution chart, HBM Holdings ranks #36 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #36 out of 941 companies for EBITDA Margin %. This places HBM Holdings in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HBM Holdings and its competitors. HBM Holdings's current EBITDA Margin % is 40.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (HKSE:02142) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$7.03, compared to a current price of HK$11.69 — trading 66.3% above its estimated fair value. The current EBITDA Margin % is 40.04%. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HBM Holdings (HKSE:02142), the current EBITDA Margin % is 40.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HKSE:02142) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of HK$11.69 is trading 66.3% above its estimated GF Value™ of HK$7.03.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:02142:
EBITDA Margin %: 40.04%
GF Value™: HK$7.03 vs. price of HK$11.69 (66.3% above fair value)
No single metric tells the full story. See the HKSE:02142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HKSE:02142
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02142 has been successfully added to your 
